Junshi Risen Pharmaceutical Technology

Junshi Risen Pharmaceutical Technology is a clinical-stage biotechnology joint venture established by Shanghai Junshi Biosciences and Risen (Suzhou) Pharmaceutical Technology. The company is dedicated to the discovery and development of innovative small molecule targeted therapies for oncology indications. Its primary pipeline assets include JS110 (RX208), a potent BRAF V600E inhibitor, and JS111, an EGFR exon 20 insertion inhibitor. The partnership combines Risen's drug discovery expertise with Junshi's robust clinical development and commercialization infrastructure in China. By focusing on high-potential targets and combination therapies, Junshi Risen aims to address significant unmet medical needs in the cancer treatment landscape.